Accuray Incorporated (ARAY) : Lapides Asset Management scooped up 21,400 additional shares in Accuray Incorporated during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 2,163,600 shares of Accuray Incorporated which is valued at $11,813,256.Accuray Incorporated makes up approximately 1.94% of Lapides Asset Management’s portfolio.
Other Hedge Funds, Including , Alambic Investment Management boosted its stake in ARAY in the latest quarter, The investment management firm added 74,340 additional shares and now holds a total of 216,310 shares of Accuray Incorporated which is valued at $1,181,053. Accuray Incorporated makes up approx 0.26% of Alambic Investment Management’s portfolio.California Public Employees Retirement System boosted its stake in ARAY in the latest quarter, The investment management firm added 46,000 additional shares and now holds a total of 105,100 shares of Accuray Incorporated which is valued at $578,050.Cypress Capital Management (wy) reduced its stake in ARAY by selling 34,100 shares or 99.74% in the most recent quarter. The Hedge Fund company now holds 90 shares of ARAY which is valued at $493. Simplex Trading sold out all of its stake in ARAY during the most recent quarter. The investment firm sold 606 shares of ARAY which is valued $3,175.
Accuray Incorporated opened for trading at $5.43 and hit $5.59 on the upside on Monday, eventually ending the session at $5.51, with a gain of 1.10% or 0.06 points. The heightened volatility saw the trading volume jump to 3,81,324 shares. Company has a market cap of $446 M.
On the company’s financial health, Accuray Incorporated reported $0.01 EPS for the quarter, beating the analyst consensus estimate by $ 0.08 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $-0.07. The company had revenue of $105.30 million for the quarter, compared to analysts expectations of $102.79 million. The company’s revenue was up 8.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.04 EPS.
Accuray Incorporated is a radiation oncology company. The Company develops manufactures sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies the CyberKnife and TomoTherapy Systems are designed to deliver treatments including radiosurgery stereotactic body radiation therapy intensity modulated radiation therapy image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH TomoHD and TomoHDA.